BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 9, 2005
View Archived Issues
Portola Series B Gets $46M For Anti-Thrombosis Work
Read More
With Lucentis BLA In Works, Genentech Reports AMD Data
Read More
Cellegy Stops Ghana HIV Trial; Broader Plans Moving Ahead
Read More
Other News To Note
Read More
Theravance Gets Telavancin Partner In Deal Worth $221M
With two Phase III programs ongoing for telavancin, Theravance Inc. found the antibiotic a global partner in Astellas Pharma Inc. through a deal worth up to $221 million. (BioWorld Today)
Read More